TVTX · Travere Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $490.73M | $233.18M | $145.24M | $212.02M | $227.49M | $198.32M |
| Cost of Revenue | $10.34M | $7.74M | $11.45M | $7.59M | $6.78M | $6.13M |
| Gross Profit | $480.39M | $225.43M | $133.79M | $204.43M | $220.71M | $192.19M |
| R&D | $206.01M | $217.50M | $244.99M | $7.50M | $210.33M | $131.77M |
| SG&A | $337.20M | $264.12M | $265.54M | $220.21M | $149.88M | $135.80M |
| Total Operating Expenses | $553.55M | $557.00M | $533.38M | $478.58M | $389.25M | $374.48M |
| D&A | $60.74M | $43.55M | $38.53M | $33.08M | $26.62M | $24.58M |
| Operating Income | ($62.82M) | ($323.83M) | ($388.14M) | ($266.57M) | ($161.76M) | ($176.16M) |
| Interest Expense | $10.75M | $11.18M | $11.30M | $11.30M | $20.10M | $19.05M |
| Income Tax | $988.0K | $120.0K | $223.0K | $313.0K | $409.0K | ($19.36M) |
| Net Income | ($25.55M) | ($321.55M) | ($111.40M) | ($278.48M) | ($180.09M) | ($169.43M) |
| EPS - Basic | ($0.29) | ($4.08) | ($1.50) | ($4.37) | ($3.56) | - |
| EPS - Diluted | ($0.29) | ($4.08) | ($1.50) | ($4.37) | ($3.56) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $93.03M | $58.53M | $58.18M | $61.69M | $165.75M | $84.77M |
| Accounts Receivable | $80.13M | $27.12M | $21.18M | $16.65M | $15.91M | $15.93M |
| Inventory | $36.16M | $6.20M | $9.41M | $6.92M | $7.31M | $7.61M |
| Accounts Payable | $24.80M | $23.53M | $41.67M | $17.29M | $15.14M | $12.13M |
| Current Assets | $437.56M | $416.70M | $616.77M | $486.44M | $582.83M | $410.41M |
| Total Assets | $605.19M | $594.13M | $788.91M | $672.59M | $776.63M | $607.44M |
| Current Liabilities | $159.90M | $200.75M | $177.91M | $142.16M | $124.09M | $92.66M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $490.36M | $535.05M | $588.10M | $629.73M | $474.52M | $396.23M |
| Stockholders' Equity | $114.83M | $59.08M | $200.81M | $42.85M | $302.11M | $211.21M |
| Retained Earnings | ($1.47B) | ($1.45B) | ($1.13B) | ($1.01B) | ($765.97M) | ($585.88M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $37.78M | ($237.47M) | ($280.02M) | ($186.29M) | ($14.79M) | ($42.74M) |
| Investing Cash Flow | $27.89M | $99.33M | $55.78M | ($32.55M) | ($137.62M) | ($61.33M) |
| Financing Cash Flow | ($33.47M) | $139.42M | $218.75M | $117.57M | $231.68M | $127.71M |
| CapEx | - | - | $668.0K | $191.0K | $5.10M | $6.77M |
| Free Cash Flow | - | - | ($280.69M) | ($186.48M) | ($19.89M) | ($49.51M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 97.9% | 96.7% | 92.1% | 96.4% | 97.0% | 96.9% |
| Operating margin | -12.8% | -138.9% | -267.2% | -125.7% | -71.1% | -88.8% |
| EBITDA margin | -0.4% | -120.2% | -240.7% | -110.1% | -59.4% | -76.4% |
| Net margin | -5.2% | -137.9% | -76.7% | -131.3% | -79.2% | -85.4% |
| Free cash flow margin | - | - | -193.3% | -88.0% | -8.7% | -25.0% |
| FCF / Net income | - | - | 2.52 | 0.67 | 0.11 | 0.29 |
| R&D / Revenue | 42.0% | 93.3% | 168.7% | 3.5% | 92.5% | 66.4% |
| SG&A / Revenue | 68.7% | 113.3% | 182.8% | 103.9% | 65.9% | 68.5% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -4.2% | -54.1% | -14.1% | -41.4% | -23.2% | -27.9% |
| Return on equity | -22.2% | -544.3% | -55.5% | -649.9% | -59.6% | -80.2% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 2.74 | 2.08 | 3.47 | 3.42 | 4.70 | 4.43 |
| Quick ratio | 2.51 | 2.04 | 3.41 | 3.37 | 4.64 | 4.35 |
| Cash ratio | 0.58 | 0.29 | 0.33 | 0.43 | 1.34 | 0.91 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -5.8x | -29.0x | -34.3x | -23.6x | -8.0x | -9.2x |
| Equity multiplier | 5.27 | 10.06 | 3.93 | 15.70 | 2.57 | 2.88 |
| Liabilities / Assets | 0.81 | 0.90 | 0.75 | 0.94 | 0.61 | 0.65 |
| Efficiency | ||||||
| Asset turnover | 0.81 | 0.39 | 0.18 | 0.32 | 0.29 | 0.33 |
| Inventory turnover | 0.29 | 1.25 | 1.22 | 1.10 | 0.93 | 0.81 |
| Days sales outstanding | 60d | 42d | 53d | 29d | 26d | 29d |
| Days inventory outstanding | 1276d | 292d | 300d | 333d | 393d | 453d |
| Days payable outstanding | 876d | 1109d | 1329d | 831d | 815d | 723d |
| Cash conversion cycle | 460d | -775d | -975d | -470d | -396d | -240d |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 29.7x | 23.3x | 3.3x | 31.3x | 4.9x | - |
| P / S | 6.9x | 5.9x | 4.6x | 6.3x | 6.5x | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 110.5% | 60.5% | -31.5% | -6.8% | 14.7% | 13.1% |
| Revenue CAGR (3y) | 32.3% | 0.8% | -9.9% | 6.5% | 19.4% | - |
| Revenue CAGR (5y) | 19.9% | 5.9% | 1.7% | - | - | - |
| Gross profit growth (YoY) | 113.1% | 68.5% | -34.6% | -7.4% | 14.8% | 13.0% |
| Operating income growth (YoY) | 80.6% | 16.6% | -45.6% | -64.8% | 8.2% | -28.2% |
| Net income growth (YoY) | 92.1% | -188.6% | 60.0% | -54.6% | -6.3% | -15.7% |
| EPS growth (YoY) | 92.9% | -172.0% | 65.7% | -22.8% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | -50.5% | -837.4% | 59.8% | 15.2% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 94.4% | -70.6% | 368.6% | -85.8% | 43.0% | -4.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$490.73M totalReportable Segment$490.73M · 100.0%
Product / service
$964.59M totalProduct$410.46M · 42.6%
FILSPARI$322.00M · 33.4%
Tiopronin Products$88.45M · 9.2%
License$80.27M · 8.3%
Market Access Milestone$40.00M · 4.1%
Regulatory Milestone$17.50M · 1.8%
Royalty$5.90M · 0.6%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-1.15
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
6/9
Neutral
- ✗Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Travere Therapeutics against the 5 most active filers in the same SIC group.